Regeneron Pharmaceuticals reported fourth‑quarter 2025 results on January 30, 2026, posting adjusted earnings of $11.44 per share—an $0.73 beat to the consensus estimate of $10.56 to $10.74—and total revenue of $3.88 billion, up 3% year‑over‑year from $3.82 billion in Q4 2024. The earnings beat was driven by a mix shift toward higher‑margin products and disciplined cost management that kept operating margins near 10%.
The company’s flagship drug Dupixent generated $4.90 billion in global net sales, with $1.486 billion attributable to the Sanofi collaboration. This collaboration revenue is higher than the $1.25 billion cited in the original article, reflecting the full share of profits from the partnership. EYLEA HD, the newer, higher‑dose formulation, grew 66% to $1.08 billion in net product sales, while legacy EYLEA sales fell 28% to $1.08 billion, underscoring the transition from the older product line. The strong performance of Dupixent and the rapid uptake of EYLEA HD offset the decline in legacy EYLEA and helped lift overall revenue.
Operating income rose to $1.12 billion, a 5% increase from $1.07 billion in Q4 2024, driven by the higher‑margin mix and modest cost inflation. Regeneron’s management highlighted that the company’s cost‑control initiatives—particularly in research and development and general & administrative expenses—kept operating leverage intact. The company’s guidance for 2026 was not disclosed, but analysts had projected revenue of $3.82 billion to $3.87 billion and adjusted EPS of $10.56 to $10.74, so the actual results exceeded expectations by $60 million to $90 million in revenue and $0.70 to $0.88 in EPS.
Dr. Leonard S. Schleifer, Regeneron’s President and CEO, said the quarter “demonstrated the strength of our four blockbuster medicines and the momentum of our late‑stage pipeline.” He added that the company’s “decades of investment in innovative science and technology” position it for future approvals and data read‑outs in 2026. The comments reinforce management’s confidence in sustaining growth while navigating the transition from legacy EYLEA to the higher‑dose product.
Market reaction to the earnings was muted. While the company beat both revenue and earnings estimates, investors focused on the year‑over‑year decline in legacy EYLEA sales and the modest 3% revenue growth, which tempered enthusiasm. The mixed sentiment reflects a cautious view of the company’s near‑term profitability amid a competitive ophthalmology market and the ongoing shift to EYLEA HD.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.